Cost-effectiveness of medicare drug plans in schizophrenia and bipolar disorder

American Journal of Managed Care

Volumn 19, Issue 2, 2013, Pages

  Smith, Kenneth J ^a   Baik, Seo Hyon ^b   Reynolds III, Charles F ^c   Rollman, Bruce L ^a   Zhang, Yuting ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

AGE; ARTICLE; BIPOLAR DISORDER; COST EFFECTIVENESS ANALYSIS; DRUG COST; ETHNICITY; GENDER; HEALTH CARE COST; HEALTH STATUS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COST-BENEFIT ANALYSIS; DRUGS, GENERIC; HUMANS; MANAGED CARE PROGRAMS; MARKOV CHAINS; MEDICARE PART D; SCHIZOPHRENIA; UNITED STATES;

EID: 84875180997     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Zhang Y, Donohue JM, Lave JR, O'Donnell G, Newhouse JP. The effect of Medicare Part D on drug and medical spending. N Engl J Med. 2009;361(1):52-61.
2. Zhang Y, Lave JR, Donohue JM, Fischer MA, Chernew ME, Newhouse JP. The impact of Medicare Part D on medication adherence among older adults enrolled in Medicare-Advantage products. Med Care. 2010;48(5):409-417.
3. Ketcham JD, Simon KI. Medicare Part D's effects on elderly patients' drug costs and utilization. Am J Manag Care. 2008;14(11) (suppl):SP14-SP22.
4. Zhang Y, Donohue JM, Newhouse JP, Lave JR. The effects of the coverage gap on drug spending: a closer look at Medicare Part D. Health Aff (Millwood). 2009;28(2):w317-w325.
5. Centers for Medicare & Medicaid Services. Prescription drug coverage-general information. http://www.cms.gov/PrescriptionDrugCov-GenIn/09- ProgramReports.asp. Published 2010. Accessed February 3, 2011.
6. Fung V, Mangione CM, Huang J, et al. Falling into the coverage gap: part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes. Health Serv Res. 2010;45(2):355-375.
7. Gu Q, Zeng F, Patel BV, Tripoli LC. Part D coverage gap and adherence to diabetes medications. Am J Manag Care. 2010;16(12):911-918.
8. Schmittdiel JA, Ettner SL, Fung V, et al. Medicare Part D coverage gap and diabetes beneficiaries. Am J Manag Care. 2009;15(3):189-193.
9. Zhang Y, Baik S, Zhou L, Reynolds CF, Lave JR. Medicare Part D's coverage gap and mental health. Presented at: 164th Annual Meeting of the American Psychiatric Association; May 14-18, 2011; Honolulu, HI.
10. Kupfer DJ, Horner MS, Brent DA, et al, eds. Oxford American Handbook of Psychiatry. 1st ed. New York: Oxford University Press; 2008.
11. Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161(15):1849-1856. (Pubitemid 32762729)
12. Henry J. Kaiser Family Foundation. The Medicare Prescription Drug Benefit. Fact Sheet. http://www.kff.org/medicare/upload/7044-05.pdf. Published November 2006. Accessed September 8, 2011.
13. Centers for Medicare & Medicaid Services. 2010 enrollment information. http://www.cms.gov/PrescriptionDrugCovGenIn/. Published 2010. Accessed November 22, 2010.
14. Kaiser Family Foundation. Low-Income Assistance Under the Medicare Drug Benefit. Fact Sheet. http://www.kff.org/medicare/upload/7327-04.pdf. Published February 2008. Accessed September 8, 2011.
15. Centers for Medicare & Medicaid Services. 2011 RxHCC model software. http://www.cms.gov/MedicareAdvtgSpecRateStats/06-Risk-adjustment. asp#TopOfPage. Published 2011. Accessed March 12, 2011.
16. Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. J Health Econ. 2004;23(3):525-542. (Pubitemid 38569537)
17. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
18. Calvert NW, Burch SP, Fu AZ, Reeves P, Thompson TR. The costeffectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder. J Manag Care Pharm. 2006;12(4):322-330. (Pubitemid 47394447)
19. Davies LM, Barnes TR, Jones PB, et al. A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. Value Health. 2008;11(4):549-562. (Pubitemid 352032801)
20. Lave JR, Keane CR, Lin CJ, Ricci EM, Amersbach G, La Vallee CP. The impact of lack of health insurance on children. J Health Soc Policy. 1998;10(2):57-73. (Pubitemid 28323008)
21. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50, 000 per qualityadjusted life-year decision rule? Med Care. 2008;46(4):349-356.
22. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146(4):473-481.
23. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637-1641. (Pubitemid 36898950)
24. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 2002;11(5):415-430. (Pubitemid 34752613)
25. Hoch JS, Rockx MA, Krahn AD. Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope. BMC Health Serv Res. 2006;6:68.